David McKenna
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
David McKenna has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Cathy Downing
Department of Maternal Fetal Medicine, Miami Valley Hospital, Dayton, USA
2 shared publications- Catrina C. Crisp
Division of Urogynecology and Pelvic Reconstructive Surgery, Department of Obstetrics and Gynecology, TriHealth/Good Samaritan Hospital, Cincinnati, OH
1 shared publication - Gabriele Saccone
Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples Federico II, Naples, Italy
1 shared publication - Jiri Sonek
Fetal Medicine Foundation USA, Dayton, OH, USA
1 shared publication - Luigi Della Corte
Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples “Federico II”, 80131 Naples, Italy
1 shared publication Melanie Glover
Wright State University Dayton, Ohio
1 shared publication
Latest Publications
- 25 January 2023
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 309 (1) , 175-181
A pragmatic evaluation of the implementation and acceptance of a universal second trimester cervical length screening program in an un-selected population
Purpose To evaluate patients' acceptance of a universal transvaginal ultrasound cervical length (CL) screening program and the feasibility of initiating treatment with progesterone in a clinical setting in women found to have a short cervix. Methods An observational, pragmatic cohort study was conducted at one tertiary care facility from 2012–2015, involving eligible women with singleton pregnancies who accepted and underwent second-trimester CL screening. The primary outcomes were the percentage of women who were eligible and accepting of screening, compliance with progesterone treatment, and the screening value of TVCL in predicting SPTB. Secondary outcomes were the number of women who received progesterone treatment and the rates of SPTB. Results Overall cervical length screening acceptance rate was found to be 82.5%. Of the 797 women that underwent screening, 21 women (2.6%) had a TVCL < 25 mm, of whom nine had a TVCL < 20.0 mm. Nineteen of the 21 women with a TVCL < 25 mm were treated with progesterone, with a 94.7% compliance rate. Delivery outcomes were obtained for 767 women. Of those with a TVCL < 25 mm, there was a 35% rate of SPTB as opposed to a 6.3% SPTB rate in those with TVCL > 25 mm. The negative predictive value for SPTB with a TVCL 25 mm or greater was 94.0%. Conclusion Universal cervical length screening was successfully implemented in 82.5% of the patient population with a high compliance rate with progesterone treatment. Furthermore, there was a higher rate of SPTB in those with a shorter cervix. Based on our outcomes obtained in an observational and pragmatic manner, we showed that incorporating second trimester transvaginal cervical length screening into routine clinical practice is readily accepted and, with the addition of vaginal progesterone treatment, may reduce the rate of prematurity.
- 25 January 2023
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 309 (1) , 175-181
A pragmatic evaluation of the implementation and acceptance of a universal second trimester cervical length screening program in an un-selected population
Purpose To evaluate patients' acceptance of a universal transvaginal ultrasound cervical length (CL) screening program and the feasibility of initiating treatment with progesterone in a clinical setting in women found to have a short cervix. Methods An observational, pragmatic cohort study was conducted at one tertiary care facility from 2012–2015, involving eligible women with singleton pregnancies who accepted and underwent second-trimester CL screening. The primary outcomes were the percentage of women who were eligible and accepting of screening, compliance with progesterone treatment, and the screening value of TVCL in predicting SPTB. Secondary outcomes were the number of women who received progesterone treatment and the rates of SPTB. Results Overall cervical length screening acceptance rate was found to be 82.5%. Of the 797 women that underwent screening, 21 women (2.6%) had a TVCL < 25 mm, of whom nine had a TVCL < 20.0 mm. Nineteen of the 21 women with a TVCL < 25 mm were treated with progesterone, with a 94.7% compliance rate. Delivery outcomes were obtained for 767 women. Of those with a TVCL < 25 mm, there was a 35% rate of SPTB as opposed to a 6.3% SPTB rate in those with TVCL > 25 mm. The negative predictive value for SPTB with a TVCL 25 mm or greater was 94.0%. Conclusion Universal cervical length screening was successfully implemented in 82.5% of the patient population with a high compliance rate with progesterone treatment. Furthermore, there was a higher rate of SPTB in those with a shorter cervix. Based on our outcomes obtained in an observational and pragmatic manner, we showed that incorporating second trimester transvaginal cervical length screening into routine clinical practice is readily accepted and, with the addition of vaginal progesterone treatment, may reduce the rate of prematurity.
- 1 March 2019
- Published by Elsevier in American Journal of Obstetrics & Gynecology MFM
- Vol. 1 (1) , 50-62
Oral progesterone for the prevention of recurrent preterm birth: systematic review and metaanalysis
- 1 March 2019
- Published by Elsevier in American Journal of Obstetrics & Gynecology MFM
- Vol. 1 (1) , 50-62
Oral progesterone for the prevention of recurrent preterm birth: systematic review and metaanalysis
- 1 December 2009
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 201 (6) , S244
676: Randomized controlled trial evaluating the effect of variable FiO2 on cesarean delivery surgical site infection
- 1 December 2009
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 201 (6) , S244
676: Randomized controlled trial evaluating the effect of variable FiO2 on cesarean delivery surgical site infection